BIRMINGHAM, Ala., March 6 /PRNewswire-FirstCall/ -- Emageon Inc. , a leading provider of enterprise visual medical systems to hospitals and healthcare networks, announced today that it has entered into a digital healthcare information management agreement with H. Lee Moffitt Cancer Center, a National Cancer Institute (NCI) - Comprehensive Cancer Center.
“We selected Emageon after an extensive review process,” said Edward Martinez, Vice President and Chief Information Officer of Moffitt Cancer Center. “Emageon’s EVMS system will provide a robust environment for logically consolidating DICOM images and delivering advanced visualization toolsets to our clinicians. This parallels our vision to have a seamless relationship among clinical results, genomic and scientific data, and images (2D, 3D, and 4D), allowing clinicians and researchers to properly review all the data associated with the case at hand. Emageon understands the practical application of diagnostic tools across the healthcare system and is strongly committed to open standards, supporting our enterprise objective for a continuum-of-care in a digitally-based work environment.”
“We are very pleased to enter this relationship with one of the country’s most prestigious cancer centers,” said Chuck Jett, Emageon’s Chairman and CEO. “We have not only been impressed by Moffitt’s technical team and expertise but also that they share our vision of integrated, enterprise imaging tools for system-wide use by diagnosticians and clinicians alike.”
About H. Lee Moffitt Cancer Center
The mission of the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida is to contribute to the prevention and cure of cancer. Moffitt’s vision is “to be the leader in scientific discovery and translation into compassionate care, cures, and prevention of cancer for our community and the world.” As it grows to fulfill its mission, the Cancer Center will continue to be distinguished by its compassionate and effective patient care.
In 2001, the National Cancer Institute awarded Moffitt the status of a Comprehensive Cancer Center in recognition of its excellence in research and contributions to clinical trials, prevention and cancer control. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in the U.S. News & World Report as one of the top cancer hospitals in America. Moffitt’s sole mission is to contribute to the prevention and cure of cancer. For more information, please visit www.moffitt.usf.edu.
About Emageon Inc.
Emageon provides an enterprise-level advanced visualization and infrastructure solution for the clinical analysis and management of digital medical images within multi-hospital networks, community hospitals and diagnostic imaging centers. Emageon’s software, including its HeartSuite set of cardiology solutions from its Camtronics subsidiary, provides physicians in multiple medical specialties such as cardiology, radiology, and orthopedics, among others, with dynamic tools to manipulate and analyze images in two and three dimensions. With these tools physicians have the ability to better understand internal anatomic structure and pathology, which can improve clinical diagnoses, disease screening and therapy planning. Emageon’s open standards-based solution is designed to help customers improve staff productivity, automate complex medical imaging workflow, lower total cost of ownership and provide better service to physicians and patients. For more information, please visit www.emageon.com.
This press release contains forward-looking statements about Emageon which represent the Company’s current views with respect to, among other things, future events and financial performance. Any forward-looking statements contained in this press release are based on Emageon’s historical performance and on current plans, beliefs and expectations. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various risks, uncertainties and other factors beyond its control. These risks, uncertainties and other factors include, among others, the risk that it may not compete successfully against larger competitors, risks associated with its history of operating losses, the risk that it may not manage its growth effectively, the risk that acquisitions could result in integration difficulties, dilution or other adverse financial consequences, risks associated with its reliance on continuing relationships with large customers, the risk of significant product errors or product failures, its reliance on reseller arrangements for important components of its solution, the risk that it may not respond effectively to changes in its industry, its customers’ reliance on third party reimbursements, and the potential impact on its business of FDA regulations and other applicable health care regulations. Additional information concerning these and other factors that could affect Emageon’s financial and operating results may be found under the heading “Risk Factors” and elsewhere in the Company’s Form 10-K for the year ended December 31, 2004, which was filed with the Securities and Exchange Commission on March 31, 2005. Emageon undertakes no obligation to update these forward-looking statements or any other information provided in this press release except as may be required by law.
Emageon Inc.
CONTACT: Bill Funderburk of Emageon, +1-205-980-7542, orbill.funderburk@emageon.com
